Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 February 2023, including: Leqembi bodes well for Biogen, Inc.; AbbVie Inc. predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche Holding AG’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Eisai’s Leqembi Launch Bodes Well For Biogen In A Pivotal Year" - Scrip, 10 Feb, 2023.)
(Also see "AbbVie Pinpoints US Humira Erosion At 37% In 2023" - Scrip, 9 Feb, 2023.)
(Also see "J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief" - Scrip, 13 Feb, 2023.)
(Also see "Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs" - Scrip, 14 Feb, 2023.)
(Also see "Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence" - Scrip, 10 Feb, 2023.)